SCHEMBL367997

SCHEMBL367997

C=CCOC(=O)C(N)CCCNC(=N)N

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DDAH1 O94760 1/20 0.43
MAPT P10636 1/20 0.36
CACNA1B Q00975 1/20 0.36
APBA1 Q02410 1/20 0.36
NPY4R P50391 7/20 0.35
NPY1R P25929 4/20 0.35
DPP7 Q9UHL4 1/20 0.33
OTC P00480 1/20 0.33
NPY2R P49146 2/20 0.33
NPY5R Q15761 2/20 0.33
ALOX15 P16050 1/20 0.33
MEN1 O00255 1/20 0.32
CYP1A2 P05177 1/20 0.32
KMT2A Q03164 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
EPHX2 P34913 1/20 0.32
TDP1 Q9NUW8 1/20 0.31
TSHR P16473 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL367998 1.00 DDAH1 (0.43) DDAH1MAPTCACNA1BAPBA1NPY4R
Hydrochloric Acid SCHEMBL3432002 0.99 DDAH1 (0.42) DDAH1MAPTCACNA1BAPBA1NPY4R
SCHEMBL26655366 0.88 DDAH1 (0.45) DDAH1MAPTCACNA1BAPBA1DPP7
SCHEMBL21327788 0.84 DDAH1 (0.41) DDAH1NPY4RNPY1RDPP7OTC
SCHEMBL8414057 0.81 NPY4R (0.38) DDAH1NPY4RNPY1RDPP7OTC
SCHEMBL11897923 0.81 NPY4R (0.38) DDAH1NPY4RNPY1RDPP7OTC
SCHEMBL28985416 0.81 DDAH1 (0.39) DDAH1NPY4RNPY1RDPP7OTC
SCHEMBL9237239 0.81 NPY4R (0.39) DDAH1NPY4RNPY1RDPP7OTC
SCHEMBL28712062 0.81 NPY4R (0.39) DDAH1NPY4RNPY1RDPP7OTC
SCHEMBL288133 0.81 NPY4R (0.39) DDAH1NPY4RNPY1RDPP7OTC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106414694-B Enzyme treatment composition 荷兰联合利华有限公司 2020-05-29 CN claimed
CN-106536700-B Filth disposal composition 荷兰联合利华有限公司 2019-03-26 CN claimed
EP-3158044-B1 ENZYME TREATMENT COMPOSITION UNILEVER PLC (GB) 2018-06-06 EP claimed
EP-3182956-A1 MOUTHWASH COMPOSITION COMPRISING A PEROXIDE SOURCE AND AN N-ACYL-L-ARGININE ALKYL ESTER SALT Colgate-Palmolive Company (US) 2017-06-28 EP claimed
EP-3158046-A1 STAIN TREATMENT COMPOSITIONS Unilever PLC (GB) 2017-04-26 EP claimed
EP-3158044-A1 ENZYME TREATMENT COMPOSITION Unilever PLC (GB) 2017-04-26 EP claimed
CN-106536700-A Stain treatment compositions 荷兰联合利华有限公司 2017-03-22 CN claimed
CN-106414694-A Enzyme treatment composition 荷兰联合利华有限公司 2017-02-15 CN claimed
WO-2016028265-A1 MOUTHWASH COMPOSITION COMPRISING A PEROXIDE SOURCE AND AN N-ACYL-L-ARGININE ALKYL ESTER SALT COLGATE-PALMOLIVE COMPANY (US) 2016-02-25 WO claimed
WO-2015193205-A1 STAIN TREATMENT COMPOSITIONS UNILEVER PLC (GB) 2015-12-23 WO claimed
WO-2015193206-A1 ENZYME TREATMENT COMPOSITION UNILEVER PLC (GB) 2015-12-23 WO claimed
US-20140179640-A1 TOPICAL COMPOSITIONS FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS EVOLOGIE LLC (US) 2014-06-26 US claimed
WO-2012177433-A1 TOPICAL COMPOSITIONS FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS EVOLOGIE LLC (US) 2012-12-27 WO claimed
CN-101262907-A Oral compositions containing cationic active ingredients COLGATE PALMOLIVE CO (US) 2008-09-10 CN claimed
EP-1904185-A2 ORAL COOMPOSITIONS HAVING CATIONIC ACTIVE INGREDIENTS Colgate-Palmolive Company (US) 2008-04-02 EP claimed
WO-2007011552-A2 ORAL COOMPOSITIONS HAVING CATIONIC ACTIVE INGREDIENTS COLGATE-PALMOLIVE COMPANY (US) 2007-01-25 WO claimed
US-20070014740-A1 Oral compositions having cationic active ingredients COLGATE-PALMOLIVE COMPANY 2007-01-18 US claimed
US-20240091112-A1 Oral Compositions and Methods COLGATE-PALMOLIVE COMPANY 2024-03-21 US disclosed
WO-2004052405-A1 ORAL FORMULATIONS FOR POORLY ABSORPTIVE HYDROPHILIC DRUGS CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2004-06-24 WO disclosed
US-5304470-A Process for the enzymatic preparation of protected and unprotected di- and oligopeptides in aqueous solutions FORSCHUNGSZENTRUM JUELICH GMBH (DE) 1994-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070014740-A1 Oral compositions having cationic active ingredients EXOSC9, TAS2R7, TAS2R39 DDAH1 2171/4885MAPT 2338/4885CACNA1B 2782/4885
US-20140179640-A1 TOPICAL COMPOSITIONS FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS TYR, ALAD, ASS1 DDAH1 2440/4885MAPT 2508/4885CACNA1B 4860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.